Herpetic vaginitis in 1993.
Substantial advances have been made in our understanding of HSV and genital herpes. The molecular biology of viral structure and function and the pathogenesis of infection have been elucidated to a large degree, and epidemiologic investigations, based on reliable type-specific assays, have been done. Diagnostic techniques have been refined, and the value of therapy has been defined. Currently, management strategies for pregnant women and their neonates are based on data rather than hypothesis, and rational counseling is feasible. The next major advance in the field would be the availability of a safe and effective vaccine, the development and investigation of which is being pursued vigorously.
Prober
C G
CG
Department of Pediatrics, Stanford University School of Medicine, CA 94305.
D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use; D017280:Condoms; D003937:Diagnosis, Differential; D005260:Female; D006176:Gynecology / Q000379:methods*; D006558:Herpes Genitalis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008403:Mass Screening; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000175:diagnosis / Q000188:drug therapy; D011256:Pregnancy Outcome; D015995:Prevalence; D011322:Primary Prevention / Q000379:methods; D012008:Recurrence; D012307:Risk Factors; D014623:Vaginal Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D017201:Virus Shedding; D014845:Vulvar Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology
D000212:Acyclovir